The latest data on myasthenia gravis (MG) research, reported at the American Association of Neuromuscular and Electrodiagnostic Medicine 2024 Annual Meeting, are presented by Dr Pushpa Narayanswami of Harvard Medical School in Boston, Massachusetts.
Dr Narayanswami begins with a safety, tolerability, and efficacy study for subcutaneous efgartigimod. Results showed that the mean change in MG activities of daily living (MG-ADL) was no different between the fixed-dose and cyclic regimens, demonstrating another dosage option for patients.
Next, Dr Narayanswami discusses two separate complement C5 inhibitor therapy trials. The first was a global registry study looking at ravulizumab. Patient cohorts consisted of those who started and remained on ravulizumab vs another that switched from initial eculizumab to ravulizumab. In both groups, MG-ADL was improved. The other study investigated zilucoplan in acetylcholine receptor autoantibody–positive generalized MG patient populations; similarly, researchers found favorable results.
She then details a study looking at the safety outcomes in pregnant patients treated with eculizumab. Because of limited disease-specific data in the registry, further investigation is recommended.
Finally, Dr Narayanaswami examines results for inebilizumab, a first-in-class anti-CD19 B cell–depleting agent. The drug demonstrated safety and beneficial efficacy compared with placebo in seropositive generalized MG patients.
--
Pushpa Narayanaswami, MD, Associate Professor, Department of Neurology, Harvard Medical School; Vice Chair of Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Pushpa Narayanaswami, MD, has disclosed the following relevant financial relationships:
Serve(d) as an advisor or consultant for: Alexion; Argenx; Janssen; Dianthus; UCB; GSK
Received research grant from: Alexion; UCB; Dianthus; Janssen